Tag:
Impax Labs
Latest Headlines
Latest Headlines
GlaxoSmithKline: Second PhIII Parkinson's drug study turns in winning data
GlaxoSmithKline says that the second of three planned Phase III studies for a reformulated Parkinson's treatment partnered with Impax Laboratories turned in positive numbers, with patients in the
Impax reveals warning letter related to drug recall
Inadequate sampling and testing has garnered Impax Labs a warning letter from the FDA for manufacturing violations. The Hayward, CA, drugmaker announced yesterday--prior to its posting on the FDA
Impax Labs' Parkinson's drug aces late-stage clinical trial
Impax Laboratories ( $IPXL ) is on a roll. The Hayward, CA-based developer announced Monday evening that the Parkinson's drug it in-licensed from GlaxoSmithKline last year--its second attempt at an
Shulman: Best biotech stocks to own
This morning, MarketWatch's Michael Shulman listed some of what he sees are the hottest bargain biotech stocks for this year: Cerus, Curis, Compugen, Spectrum Pharmaceuticals and Impax Laboratories.
Impax snares $186M deal from GSK on late-stage Parkinson's drug
With investigators at Impax Pharmaceuticals ( $IPXL ) preparing to reap a final round of late-stage data for their Parkinson's drug IPX066, GlaxoSmithKline ( $GSK ) has stepped up to license marketing
